Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer

Value Health. 2014 Nov;17(7):A632. doi: 10.1016/j.jval.2014.08.2264. Epub 2014 Oct 26.

Authors

C N Graham¹, G Hechmati², J Hjelmgren², F De Liège³, J Lanier³, A Knoof³, H Knox¹, B Barber⁴, G de Pouvourville⁵

Affiliations

¹ RTI Health Solutions, Research Triangle Park, NC, USA.
² Amgen (Europe) GmbH, Zug, Switzerland.
³ Amgen France SAS, Neuilly-sur-Seine, France.
⁴ Amgen, Inc., Thousand Oaks, CA, USA.
⁵ ESSEC Business School, Cergy-Pontoise, France.

PMID: 27202247
DOI: 10.1016/j.jval.2014.08.2264

No abstract available